1 Harry O, Yasin S, Brunner H. Childhood-onset systemic lupus erythematosus: a review and update[J]. J Pediatr, 2018, 196: 22-30.e2. PMID: 29703361. DOI: 10.1016/j.jpeds.2018.01.045.
2 Lockshin MD, Barbhaiya M, Izmirly P, et al. SLE: reconciling heterogeneity[J]. Lupus Sci Med, 2019, 6(1): e000280. PMID: 31080630. PMCID: PMC6485210. DOI: 10.1136/lupus-2018-000280.
3 Silva CA, Avcin T, Brunner HI. Taxonomy for systemic lupus erythematosus with onset before adulthood[J]. Arthritis Care Res (Hoboken), 2012, 64(12): 1787-1793. PMID: 22730317. PMCID: PMC3463746. DOI: 10.1002/acr.21757.
4 Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78(6): 736-745. PMID: 30926722. DOI: 10.1136/annrheumdis-2019-215089.
5 Al Sawah S, Zhang X, Zhu BJ, et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus—the Hopkins Lupus Cohort[J]. Lupus Sci Med, 2015, 2(1): e000066. PMID: 25861455. PMCID: PMC4378372. DOI: 10.1136/lupus-2014-000066.
6 Kleinmann JF, Tubach F, Le Guern V, et al. International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus[J]. Autoimmun Rev, 2017, 16(6): 650-657. PMID: 28434948. DOI: 10.1016/j.autrev.2017.04.011.
7 Tsokos GC, Lo MS, Reis PC, et al. New insights into the immunopathogenesis of systemic lupus erythematosus[J]. Nat Rev Rheumatol, 2016, 12(12): 716-730. PMID: 27872476. DOI: 10.1038/nrrheum.2016.186.
8 Tipton CM, Hom JR, Fucile CF, et al. Understanding B-cell activation and autoantibody repertoire selection in systemic lupus erythematosus: a B-cell immunomics approach[J]. Immunol Rev, 2018, 284(1): 120-131. PMID:29944759. PMCID:PMC6022284. DOI: 10.1111/imr.12660.
9 Baker KP, Edwards BM, Main SH, et al. Generation and characterization of lymphostat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator[J]. Arthritis Rheum, 2003, 48(11): 3253-3265. PMID: 14613291. DOI: 10.1002/art.11299.
10 Guzman M, Hui-Yuen JS. Management of pediatric systemic lupus erythematosus: focus on belimumab[J]. Drug Des Devel Ther, 2020, 14: 2503-2513. PMID: 32612353. PMCID: PMC7323799. DOI: 10.2147/DDDT.S216193.
11 佚名. 葛兰素贝利尤单抗(Belimumab)进口注册申请获国家药监批准[J]. 临床合理用药杂志, 2019, 12(20): 72.
12 Levy RA, Gonzalez-Rivera T, Khamashta M, et al. 10 Years of belimumab experience: what have we learnt?[J]. Lupus, 2021.PMID: 34238087. DOI: 10.1177/09612033211028653. Epub ahead of print.
13 Brunner HI, Abud-Mendoza C, Viola DO, et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial[J]. Ann Rheum Dis, 2020, 79(10): 1340-1348. PMID: 32699034. PMCID: PMC7509523. DOI: 10.1136/annrheumdis-2020-217101.
14 罗蕾, 黄文瀚, 任飞凤, 等. 7例贝利尤单抗治疗系统性红斑狼疮的有效性和安全性分析[J]. 重庆医科大学学报, 2021, 1-4. DOI: 10.13406/j.cnki.cyxb.002732.
15 Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2011, 377(9767): 721-731. PMID: 21296403. DOI: 10.1016/S0140-6736(10)61354-2.
16 Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus[J]. Arthritis Rheum, 2011, 63(12): 3918-3930. PMID: 22127708. PMCID: PMC5007058. DOI: 10.1002/art.30613.
17 Wallace DJ, Ginzler EM, Merrill JT, et al. Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus[J]. Arthritis Rheum, 2019, 71(7): 1125-1134. PMID: 30771238. PMCID: PMC6617785. DOI: 10.1002/art.40861.
18 Iaccarino L, Andreoli L, Bocci EB, et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study[J]. J Autoimmun, 2018, 86: 1-8. PMID: 28935492. DOI: 10.1016/j.jaut.2017.09.004.
19 Tanaka Y, Bae SC, Bass D, et al. Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea[J]. RMD Open, 2021, 7(2): e001629. PMID: 34215703. PMCID: PMC8256836. DOI: 10.1136/rmdopen-2021-001629.
20 Suso JP, Posso-Osorio I, Jiménez CA, et al. Profile of BAFF and its receptors' expression in lupus nephritis is associated with pathological classes[J]. Lupus, 2018, 27(5): 708-715. PMID: 29087261. DOI: 10.1177/0961203317739132.
21 Hui-Yuen JS, Reddy A, Taylor J, et al. Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices[J]. J Rheumatol, 2015, 42(12): 2288-2295. PMID: 26523030. PMCID: PMC5031077. DOI: 10.3899/jrheum.150470.
22 Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis[J]. N Engl J Med, 2020, 383(12): 1117-1128. PMID: 32937045. DOI: 10.1056/NEJMoa2001180.
23 徐甜, 施璇, 谢筱彤, 等. 贝利尤单抗在一例活动性狼疮肾炎年轻女性患者中的应用[J]. 中华肾脏病杂志, 2021, 37(4): 366-368. DOI: 10.3760/cma.j.cn441217-20200707-00053.
24 Kraaij T, Arends EJ, van Dam LS, et al. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results[J]. Nephrol Dial Transplant, 2021, 36(8): 1474-1483. PMID: 32591783. PMCID: PMC8311580. DOI: 10.1093/ndt/gfaa117.
25 Tarr T, Dérfalvi B, Gy?ri N, et al. Similarities and differences between pediatric and adult patients with systemic lupus erythematosus[J]. Lupus, 2015, 24(8): 796-803. PMID: 25516474. DOI: 10.1177/0961203314563817.
26 Zhang FC, Bae SC, Bass D, et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea[J]. Ann Rheum Dis, 2018, 77(3): 355-363. PMID: 29295825. PMCID: PMC5867402. DOI: 10.1136/annrheumdis-2017-211631.
27 Ferreira JCOA , Trindade VC, Espada G, et al. Epidemiology and management practices for childhood-onset systemic lupus erythematosus patients: a survey in Latin America[J]. Clin Rheumatol, 2018, 37(12): 3299-3307. PMID: 30094748. DOI: 10.1007/s10067-018-4254-4.
28 Fontana F, Alfano G, Leonelli M, et al. Efficacy of belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report[J]. BMC Nephrol, 2018, 19(1): 276. PMID: 30342482. PMCID: PMC6196012. DOI: 10.1186/s12882-018-1066-3.
29 张涛, 李国民, 刘海梅, 等. 贝利尤单抗治疗儿童神经精神狼疮1例病例报告[J]. 中国循证儿科杂志, 2020, 15(5): 391-393. DOI: 10.3969/j.issn.1673-5501.2020.05.015.
30 朱万红, 王秀丽, 赵成广, 等. 贝利尤单抗治疗以呕吐尿频为首发症状的儿童系统性红斑狼疮一例[J]. 国际儿科学杂志, 2021, 48(3): 214-216. DOI: 10.3760/cma.j.issn.1673-4408.2021.03.016.
31 Dimelow R, Ji B, Struemper H. Pharmacokinetics of belimumab in children with systemic lupus erythematosus[J]. Clin Pharmacol Drug Dev, 2021, 10(6): 622-633. PMID: 33245847. PMCID: PMC8246766. DOI: 10.1002/cpdd.889.
32 Nino A, Bass DL, Eriksson G, et al. Efficacy and safety of intravenous belimumab in children with systemic lupus erythematosus: an across-trial comparison with the adult belimumab studies[J]. Arthritis Rheum, 2019, 71(suppl 10): 5083-5085.
33 Sheikh S, Scheinberg M, Wei JCC, et al. Headline results for a phase 4, 52-week, randomised, double-blind, placebo-controlled study to assess adverse envents of special interest (AESI) in adults with active, autoantibody-positive system lupus erythematosus (SLE) receiving belimumab[J]. Ann Rheum Dis, 2019, 78: 266.
34 佚名. 英国警示贝利木单抗严重精神不良事件发生增加的风险[J]. 中国医药导刊, 2019, 21(8): 487.
35 Wallace DJ, Navarra S, Petri MA, et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus[J]. Lupus, 2013, 22(2): 144-154. PMID: 23213069. DOI: 10.1177/0961203312469259.
36 Fredericks CA, Kvam KA, Bear J, et al. A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab[J]. Lupus, 2014, 23(7): 711-713. PMID: 24531080. DOI: 10.1177/0961203314524292.
37 Leblanc-Trudeau C, Masetto A, Bocti C. Progressive multifocal leukoencephalopathy associated with belimumab in a patient with systemic lupus erythematosus[J]. J Rheumatol, 2015, 42(3): 551-552. PMID: 25729044. DOI: 10.3899/jrheum.140577.
38 Benvenuti F, Gatto M, Doria A. A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab—comments on article by Fredericks et al[J]. Lupus, 2014, 23(13): 1445-1446. PMID: 25107935. DOI: 10.1177/0961203314545800.
39 Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis[J]. Ann Rheum Dis, 2020, 79(6): 713-723. PMID: 32220834. DOI: 10.1136/annrheumdis-2020-216924.
40 中华医学会风湿病学分会, 国家皮肤与免疫疾病临床医学研究中心, 中国系统性红斑狼疮研究协作组. 2020中国系统性红斑狼疮诊疗指南[J]. 中华内科杂志, 2020, 59(3): 172-185. PMID: 32146743. DOI: 10.3760/cma.j.issn.0578-1426.2020.03.002.
41 Trindade VC, Carneiro-Sampaio M, Bonfa E, et al. An update on the management of childhood-onset systemic lupus erythematosus[J]. Paediatr Drugs, 2021, 23(4): 331-347. PMID: 34244988. PMCID: PMC8270778. DOI: 10.1007/s40272-021-00457-z.